Taysha Gene Therapies (TSHA) Return on Sales (2023 - 2026)

Taysha Gene Therapies has disclosed Return on Sales across 4 years of filings, most recently posting 0.38% for Q1 2026.

• Return on Sales for Q1 2026 came in at 0.38%, down 29.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.38% (down 27.0% YoY), and the FY2025 annual result was 0.18%, down 8.0% from the prior year.
• Return on Sales came in at 0.38% for Q1 2026 at Taysha Gene Therapies, down from 0.21% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.04% in Q3 2023 to a low of 0.38% in Q1 2026.
• The 4-year median for Return on Sales is 0.1% (2023), against an average of 0.13%.
• Across the five-year window, Return on Sales gained 5 bps in 2025 and slipped 29 bps in 2026, its largest moves.
• Taysha Gene Therapies' Return on Sales stood at 0.04% in 2023, then slumped by 116 bps to 0.09% in 2024, then slumped by 133 bps to 0.21% in 2025, then tumbled by 82 bps to 0.38% in 2026.
• The last three Return on Sales figures came in at 0.38% (Q1 2026), 0.21% (Q4 2025), and 0.15% (Q3 2025), per Business Quant data.